Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain
- 472 Downloads
Background and Objective
Omalizumab is a humanized monoclonal antibody that targets circulating immunoglobulin E molecules to treat severe uncontrolled asthma. The aim of this study was to determine the cost effectiveness of omalizumab compared with standard treatment for the control of severe persistent asthma according to data from patients treated in a specialized asthma unit.
This was an observational, retrospective, single-center study in the setting of the Pulmonology and Respiratory Allergy Service, Thorax Institute, Hospital Clínic de Barcelona, Barcelona, Spain. Data were collected by review of medical records of 86 uncontrolled severe persistent asthma patients treated with omalizumab from January 2005 to April 2014. Effectiveness was assessed by the reduction in asthma exacerbations and 3-point increases in the Asthma Control Test (ACT) score. The economic evaluation was performed from the societal perspective, including direct health costs (resource use and drug treatments) and indirect costs (disease impact on labor productivity) in 2016 Euros. The time horizon was 12 months before and after the initiation of treatment with omalizumab. Results were expressed using the incremental cost-effectiveness ratio (ICER).
Taking into account only direct costs, the ICERs were €1487.46 (95 % confidence interval [CI] 1241.21–1778.34) per exacerbation avoided and €5425.13 (95 % CI 4539.30–6551.03) per 3-point increase in the ACT. When indirect costs were included, the ICERs were €1130.93 (95 % CI 909.08–1392.86) per exacerbation avoided, and €4124.79 (95 % CI 3281.69–5186.73) per 3-point increase in the ACT.
The results of this study confirm the effectiveness of the addition of omalizumab to standard therapy in patients with uncontrolled severe persistent asthma.
KeywordsAsthma Indirect Cost Salmeterol Asthma Control Asthma Exacerbation
María del Carmen Vennera, Antonio Valero, Estefany Uria, Carles Forné, and César Picado conceived and designed the study. Estefany Uria and Carles Forné performed the data analysis, obtained the results, and drafted the manuscript. All authors contributed to the writing and review of the manuscript, and read and accepted the final manuscript. María del Carmen Vennera acts as overall guarantor of the manuscript.
Compliances with Ethical Standards
This study was funded by Novartis International AG.
Conflict of interest
This study was carried out with the financial collaboration of Novartis. Estefany Uria and Carles Forné are employed by Oblikue Consulting, which received financing from Novartis to carry out the study. María del Carmen Vennera, Antonio Valero, and César Picado have received funding for attending meetings, courses and congresses (Novartis). The authors alone are responsible for the content and writing of the paper.
- 1.Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. GINA 2015. Available at: http://www.ginasthma.org/. Accessed 15 Mar 2016.
- 7.Borderias Clau L, Zabaleta Murguionda M, Riesco Miranda JA, Pellicer Ciscar C, Hernandez Hernandez JR, Carrillo Diaz T, et al. Cost and management of asthma exacerbations in Spanish hospitals (COAX study in hospital services) [in Spanish]. Arch Bronconeumol. 2005;41(6):313–21 (Spanish).Google Scholar
- 8.Summary of product characteristics: Xolair. Novartis International AG. April 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf. Accessed 15 Mar 2016.
- 17.Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16.CrossRefPubMedGoogle Scholar
- 31.Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231–50.CrossRefPubMedGoogle Scholar
- 32.Lopez Bastida J, Oliva J, Antoñanzas F, Garcia-Altes A, Gisbert R, Mar J, et al. A proposed guideline for economic evaluation of health technologies [in Spanish]. Gac Sanit. 2010;24(2):154–70.Google Scholar
- 34.National Institute for Health and Clinical Excellence (NICE). Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201). NICE 2013. Available at: http://www.nice.org.uk/guidance/ta278/. Accessed 8 Oct 2014.
- 36.Levy AN, García a Ruiz AJ, García-Agua Soler N, Sanjuan MV. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205–10.Google Scholar
- 37.Spanish Guidelines for Asthma Management (GEMA) [Guía Española para el Manejo del Asma (GEMA 4.0)]. Editorial: Luzan 5 Madrid; 2015.Google Scholar
- 41.Gisbert R, Brosa M. Spanish health care costs database: eSalud. Oblikue Consulting, S.L., Barcelona. Updated 2015. Available at: http://www.oblikue.com/bddcostes/. Accessed 15 Mar 2016.
- 42.Ministry of Health, Social Services and Equality [Ministerio de Sanidad, Servicios Sociales e Igualdad, MSSSI]. Minimum Basic Data Set-Hospital Discharge (MBDS-HD) [Conjunto Mínimo Básico de Datos, CMBD]. Updated 2013. Available at: http://pestadistico.inteligenciadegestion.msssi.es/. Accessed 15 Mar 2016.
- 43.General Council of the Association of Official Pharmacists. General Council of the Association of Official Pharmacists Database: Bot PLUS 2.0. Available at: https://botplusweb.portalfarma.com/. Accessed 15 Mar 2016.
- 44.Royal Decree-Law 8/2010. Extraordinary measures to reduce the public deficit. Amended by the Royal Decree-Law 9/2011.Google Scholar
- 50.R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna; 2015. Available at: http://www.Rproject.org/.
- 56.Campbell JD, McQueen RB, Briggs A. The “e” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc. 2014;11(Suppl 2):S105–11.Google Scholar
- 61.Plaza V, Cobos A, Ignacio-Garcia JM, Molina J, Bergoñon S, Garcia-Alonso F, et al. Cost-effectiveness of an intervention based on the Global INitiative for Asthma (GINA) recommendations using a computerized clinical decision support system: a physicians randomized trial [in Spanish]. Med Clin (Barc). 2005;124(6):201–6.CrossRefPubMedGoogle Scholar